ARPO
Income statement / Annual
Last year (2024), Aerpio Pharmaceuticals, Inc.'s total revenue was $25.98 M,
an increase of 371.73% from the previous year.
In 2024, Aerpio Pharmaceuticals, Inc.'s net income was -$63.69 M.
See Aerpio Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$25.98 M |
$5.51 M |
$4.47 M |
$823.00 K |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$35.02 M
|
$20.02 M
|
$14.44 M
|
$8.32 M
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
-$29.51 M
|
-$15.54 M
|
-$13.62 M
|
-$8.32 M
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
-5.36
|
-3.47
|
-16.55
|
0
|
0
|
0
|
| Research and Development Expenses |
$51.03 M
|
$35.02 M
|
$20.02 M
|
$14.44 M
|
$9.82 M
|
$15.14 M
|
$12.75 M
|
| General & Administrative Expenses |
$0.00
|
$7.44 M
|
$8.28 M
|
$7.97 M
|
$8.17 M
|
$2.52 M
|
$2.71 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.50 M
|
$1.40 M
|
$1.37 M
|
| Selling, General & Administrative Expenses |
$36.75 M
|
$7.44 M
|
$8.28 M
|
$7.97 M
|
$9.67 M
|
$3.92 M
|
$4.08 M
|
| Other Expenses |
$5.66 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$93.44 M
|
$7.44 M
|
$7.56 M
|
$7.96 M
|
$10.32 M
|
$15.93 M
|
$15.33 M
|
| Cost And Expenses |
$0.00
|
$42.45 M
|
$27.57 M
|
$22.40 M
|
$18.64 M
|
$15.93 M
|
$15.33 M
|
| Interest Income |
$3.93 M
|
$29.00 K
|
$59.00 K
|
$600.00 K
|
$835.00 K
|
$768.00 K
|
$202.00 K
|
| Interest Expense |
-$154.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$892.00 K
|
$1.17 M
|
$1.11 M
|
$1.35 M
|
$1.35 M
|
$1.53 M
|
| EBITDA |
-$67.46 M |
-$36.05 M |
-$22.65 M |
-$20.47 M |
-$16.64 M |
-$9.54 M |
-$13.92 M |
| EBITDA Ratio |
-2.6
|
-6.55
|
-5.06
|
-24.88
|
0
|
0
|
0
|
| Operating Income Ratio |
-2.6
|
-6.71
|
-5.32
|
-26.23
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$3.77 M
|
$29.00 K
|
$667.00 K
|
-$594.00 K
|
-$1.49 M
|
-$5.81 M
|
$330.00 K
|
| Income Before Tax |
-$63.69 M
|
-$36.92 M
|
-$23.16 M
|
-$22.18 M
|
-$19.48 M
|
-$16.70 M
|
-$15.13 M
|
| Income Before Tax Ratio |
-2.45
|
-6.7
|
-5.18
|
-26.95
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$63.69 M
|
-$36.92 M
|
-$23.16 M
|
-$22.18 M
|
-$19.48 M
|
-$16.70 M
|
-$15.13 M
|
| Net Income Ratio |
-2.45
|
-6.7
|
-5.18
|
-26.95
|
0
|
0
|
0
|
| EPS |
-2.36 |
-1.08 |
-0.96 |
-1.35 |
-2.43 |
-3.59 |
-2.25 |
| EPS Diluted |
-2.36 |
-1.08 |
-0.96 |
-1.35 |
-2.43 |
-3.59 |
-2.25 |
| Weighted Average Shares Out |
$27.03 M
|
$34.29 M
|
$24.10 M
|
$16.42 M
|
$7.64 M
|
$4.65 M
|
$6.74 M
|
| Weighted Average Shares Out Diluted |
$27.03 M
|
$34.29 M
|
$24.10 M
|
$16.42 M
|
$8.01 M
|
$4.65 M
|
$6.74 M
|
| Link |
|
|
|
|
|
|
|
